Sickle Cell Anemia Testing and Screening Market Size & Growth Forecast 2026–2035, By Segments (Age Group, Sector Type, Technology), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Sickle Cell Anemia Testing and Screening Market size was more than USD 462.96 Million in 2025 and is set to grow at a 12% CAGR between 2026 and 2035, attaining USD 1.44 Billion by 2035. The industry revenue for 2026 is calculated at USD 512.56 million.

• Base Year Value (2025): USD 462.96 Million
• CAGR (2026-2035): 12%
• Forecast Year Value (2035): USD 1.44 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Sickle Cell Anemia Testing and Screening Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America holds 46.64% share due to established newborn screening programs, strong diagnostic lab access, and structured care pathways linking screening with confirmatory testing and disease management.
  • Europe’s 13.44% CAGR is driven by expanding screening protocols, integration into public health systems, and stronger referral pathways enabling earlier detection and higher diagnostic testing volumes.

• Segment Momentum:

  • Newborn Screening accounted for a 44.63% share in 2025 because it is embedded in standardized neonatal and pediatric care pathways, making early-life testing a consistent and routine source of screening demand.
  • Private Labs are growing rapidly as healthcare providers and patients seek faster processing, greater accessibility, and more flexible testing services beyond traditional public laboratory networks.

• Market Expansion Drivers:

  • Increasing prevalence in high-risk populations driving urgent early diagnostic demand.
  • Advancements in PCR and genetic testing enabling faster accurate diagnostics.
  • Government-led newborn screening and elimination missions expanding population-wide testing.

• Leading Market Participants:

  Prominent companies in the sickle cell anemia testing and screening market include Roche Diagnostics (Switzerland), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (USA), Bio-Rad Laboratories, Inc. (USA), Laboratory Corporation of America Holdings (USA), Quest Diagnostics Incorporated (USA), Streck, Inc. (USA), Daktari Diagnostics (USA), Hemex Health, Inc. (USA), BIOMEDOMICS INC (USA).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 462.96 Million
  • Projected Market Size: USD 1.44 Billion by 2035
  • Growth Forecasts: 12% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Europe
  • Core Revenue Segment: Newborn Screening (12 Months and Below) (Age Group) | Government Labs (Sector Type) | Hemoglobin Electrophoresis (Technology)
  • Emerging Opportunity Segment: Adult Screening (25 to 60 Years) (Age Group) | Private Labs (Sector Type) | Point-of-Care Tests (Technology)

Market Growth Drivers and Industry Trends

Increasing prevalence in high-risk populations driving urgent early diagnostic demand

Rising disease burden in populations with higher genetic susceptibility is pushing healthcare systems, maternity centers, and primary care networks to identify sickle cell disease earlier rather than waiting for symptomatic presentation. In the sickle cell anemia testing and screening market, This transitions purchasing and clinical practice toward routine carrier screening, prenatal assessment, and early-life diagnostic testing, particularly in regions where family history and inherited risk are well recognized by providers. As case recognition improves, laboratories and hospital networks face stronger pressure to expand testing access, shorten turnaround times, and integrate confirmatory pathways, directly driving demand for the market through a more urgent and repeatable diagnostic workflow.

Advancements in PCR and genetic testing enabling faster accurate diagnostics

Improved PCR platforms and genetic testing methods are changing the economics and clinical utility of diagnosis by making results more precise, scalable, and actionable at earlier stages of care. For the sickle cell anemia testing and screening market, faster and more accurate detection reduces dependence on slower or less definitive pathways, encouraging hospitals, specialty labs, and screening programs to adopt molecular techniques for confirmation, carrier identification, and differentiation from related hemoglobin disorders. This strengthens market development by increasing confidence in test performance, supporting broader integration into standardized diagnostic protocols, and expanding the role of testing in both newborn and family-based screening decisions.

Government-led newborn screening and elimination missions expanding population-wide testing

Public health mandates and national screening initiatives translate directly into sustained testing volumes because they move sickle cell detection from selective use into organized, protocol-driven care. In the sickle cell anemia testing and screening market, government-backed newborn screening and elimination programs create structured demand through centralized procurement, reimbursement support, and mandatory testing pathways tied to maternal and child health services. That policy-led expansion increases market penetration by extending access beyond specialist centers, bringing public laboratories, regional hospitals, and community health systems into formal screening networks that require dependable test supply, confirmatory capacity, and long-term program continuity.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Increasing prevalence in high-risk populations driving urgent early diagnostic demand	2.50%	High	Africa, Asia Pacific	High	Near Term
Advancements in PCR and genetic testing enabling faster accurate diagnostics	2.70%	Moderate	Global	High	Mid Term
Government-led newborn screening and elimination missions expanding population-wide testing	1.80%	High	Africa, Asia Pacific	High	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Europe (Fastest-Growing Region)

North America held a 46.64% share of the sickle cell anemia testing and screening market in 2025, backed by established newborn screening programs, broad access to diagnostic laboratories, and routine use of confirmatory testing across hospital and specialty care settings. The region’s leadership is strengthened by structured care pathways that connect early screening with follow-up diagnosis and disease management, allowing testing volumes to remain consistently high. Market activity is also underpinned by the presence of advanced healthcare infrastructure and stronger awareness among clinicians, which helps embed screening into standard practice rather than limiting it to selective testing.

Europe is projected to expand at a 13.44% CAGR over the forecast period in the sickle cell anemia testing and screening market, driven by wider adoption of screening protocols and increasing integration of early detection into public health systems. Growth is accelerating as more healthcare providers incorporate screening for at-risk populations and strengthen referral links between maternity care, laboratories, and hematology services. In practice, this improves case identification earlier in the care pathway and increases demand for both initial screening and confirmatory diagnostic testing across the region.

Key Country Insights

United States

Comprehensive Screening Programs

The U.S. sickle cell anemia testing and screening market benefits from established newborn screening programs and increasing access to advanced diagnostic technologies. Healthcare organizations are improving laboratory workflows and expanding confirmatory testing to support earlier clinical intervention.

Japan

Targeted Diagnostic Expansion

Japan is gradually expanding sickle cell anemia testing capabilities in response to increasingly diverse patient populations and specialized clinical requirements. Healthcare institutions are improving access to accurate laboratory diagnostics and efficient screening workflows where appropriate.

South Korea

Laboratory Capability Enhancement

South Korea is reinforcing sickle cell anemia testing capacity through investments in modern laboratory technologies and improved diagnostic processes. Clinical laboratories are emphasizing timely and accurate screening while supporting healthcare providers with dependable confirmatory testing services.

Germany

Diagnostic Accuracy Focus

Germany is strengthening sickle cell anemia testing through standardized laboratory practices and broader awareness of inherited blood disorders. Diagnostic providers are enhancing testing precision and supporting healthcare professionals with reliable screening and confirmatory solutions.

France

Early Detection Support

France is advancing sickle cell anemia testing through structured screening initiatives and greater emphasis on early diagnosis in appropriate populations. Diagnostic laboratories are expanding efficient testing capabilities that support timely clinical decision-making and patient management.

Italy

Clinical Testing Development

Italy is strengthening sickle cell anemia testing by improving laboratory infrastructure and expanding awareness among healthcare providers. Diagnostic service providers are focusing on dependable screening workflows and confirmatory testing to support accurate diagnosis and effective patient care.

Segment Leadership and Growth Trends

  Age Group Segment Analysis: Newborn Screening (12 Months and Below) (Largest Segment) vs Adult Screening (25 to 60 Years) (Fastest-Growing Segment)

Newborn Screening (12 Months and Below) held the dominant position in the sickle cell anemia testing and screening market in 2025, accounting for a 44.63% share. its position is maintained through the routine nature of early-life screening within structured testing pathways, where detection at birth or shortly after remains the most established point of intervention. This makes Newborn Screening a consistent volume driver in the sickle cell anemia testing and screening market, as testing is embedded into standardized pediatric and neonatal care workflows rather than depending on symptom-led demand.

Adult Screening (25 to 60 Years) is emerging as the fastest-growing segment in the sickle cell anemia testing and screening market because screening needs in this age group are becoming more active beyond traditional early-life diagnosis channels. Growth is being aided by the practical need to identify previously undiagnosed cases, confirm disease status, or expand screening access among adults who were not covered through newborn programs. Compared with infant-focused pathways, Adult Screening is gaining momentum as the market broadens from routine neonatal detection toward wider population coverage and later-stage diagnostic follow-up.

Sector Type Segment Analysis: Government Labs (Largest Segment) vs Private Labs (Fastest-Growing Segment)

In 2025, Government Labs represented the largest segment in the sickle cell anemia testing and screening market with a 40.92% share. Their leadership reflects the central role of public testing infrastructure in delivering broad screening coverage, especially where sickle cell testing is tied to organized health programs and public laboratory networks. Government Labs maintain this position because they are typically integrated into large-scale screening operations, allowing them to handle consistent testing volumes across established care pathways.

Private Labs are the fastest-growing segment in the sickle cell anemia testing and screening market as demand shifts toward more flexible and accessible testing channels. Their momentum is aided by the ability to respond quickly to rising screening requirements, particularly where patients and providers seek faster processing, easier access, or expanded testing availability outside public systems. Relative to government-run facilities, Private Labs are benefiting from the market’s gradual move toward more decentralized and service-oriented diagnostic access.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Age Group	Newborn Screening (12 Months and Below), Adult Screening (25 to 60 Years), Other Age Groups (1 to 25 & Above 60 Years)	Newborn Screening (12 Months and Below)	Adult Screening (25 to 60 Years)
Sector Type	Government Labs, Private Labs, Corporate Labs, PPP (Public-Private-Partnerships)	Government Labs	Private Labs
Technology	Hemoglobin Electrophoresis, High-Performance Liquid Chromatography (HPLC), Point-of-Care Tests, Others	Hemoglobin Electrophoresis	Point-of-Care Tests

Competitive Landscape and Market Positioning

Prominent players in the sickle cell anemia testing and screening market:

1. Roche Diagnostics (Switzerland)

2. Siemens Healthineers AG (Germany)

3. Thermo Fisher Scientific Inc. (USA)

4. Bio-Rad Laboratories Inc. (USA)

5. Laboratory Corporation of America Holdings (USA)

6. Quest Diagnostics Incorporated (USA)

7. Streck Inc. (USA)

8. Daktari Diagnostics (USA)

9. Hemex Health Inc. (USA)

10. BIOMEDOMICS INC (USA)

Increasing awareness of early disease detection and genetic screening programs is significantly influencing the sickle cell anemia testing and screening market. Market participants are prioritizing the development of rapid diagnostic methods, automated screening technologies, and improved laboratory efficiency to support broader healthcare accessibility. Demand for accurate and cost-effective testing solutions is also rising as healthcare systems strengthen preventive screening initiatives and newborn testing programs.

Industry Development/News

Company Name	Date	Key Development
Bio-Rad Laboratories	Oct-24	Bio-Rad Laboratories introduced the Vericheck ddPCR Empty-Full Capsid Kit using Droplet Digital PCR technology to assess AAV sample capsid and genome titers. The kit enables precise quantification of full capsids, supporting gene therapy development workflows and improving analytical accuracy and regulatory compliance in advanced biological testing environments.
Streck	Apr-24	Streck launched Protein Plus BCT, a specialized blood collection tube designed to stabilize protein concentrations during storage. The product supports downstream mass spectrometry and immunoassay testing by preserving sample integrity, improving logistical flexibility for laboratories conducting protein-based diagnostic and analytical workflows in clinical research and testing environments.